Can hospitals study dementia-drug signals without sharing patient records? A federated method matched pooled estimates—but did not prove treatments work
FLAT-WHITE reproduced centralized estimates from four US health-data networks using one exchange of summary statistics. Twenty-one drug associations also appeared in a 339,180-person external cohort, but residual confounding means none is a treatment recommendation.
The short version
- What happened
- The method exchanged summary statistics once across four US learning-health systems and reproduced the effect estimates and standard errors of a centralized pooled analysis.
- Who it affects
- Hospitals may be able to collaborate without exporting patient-level records, but people with memory problems should not change medication on the basis of these retrospective signals.
- What remains unproven
- Retrospective electronic-health-record study
Keep in mind
Retrospective electronic-health-record study
Residual confounding and informative censoring remain possible
Drug exposure was simplified to binary initiation
Common outcome-model assumption across sites
Odds ratios do not directly express absolute risk
No randomized treatment or patient-facing outcome trial
Source analysis · 1 linked source. Primary analysed source date: 27 October 2026.
Keep following the evidence
Join The Impact Brief founding list for selected AI reports, their effect on people and the evidence limits. Read a sample first.
Read the full report · 4 min The evidence, methods, implications and limitations
One exchange of summaries reproduced the pooled calculation
A peer-reviewed study reports a way for hospitals to run large observational treatment comparisons without sending patient-level records to a central repository. FLAT-WHITE fits propensity-score models locally, applies overlap weights, then transmits summary statistics once. A coordinating site reconstructs the combined likelihood and calibrates estimates with negative-control outcomes. In the paper's tests, the federated estimates and standard errors were nearly identical to those produced by pooling the individual records.
That is a technical result, not a new therapy. The useful advance is that research partners with legal or governance barriers to sharing records may be able to ask the same prespecified question across sites while keeping identifiable-level data behind each institution's boundary. It could make otherwise impossible comparisons feasible without treating federated analysis as anonymous or risk-free. The approach also reduces repeated communication between sites, although it still depends on common definitions, harmonised covariates and correct local implementation.[1]
The dementia case study was large—and still observational
The researchers applied the framework to 123,971 people aged 50 or older with mild cognitive impairment across INSIGHT, OneFlorida+, Penn Medicine and Yale New Haven. They emulated 42,700 single-site and 9,050 multi-site comparisons for 181 prescribed drugs, using 29 supplements as the main active-control group and following records for a dementia diagnosis, loss to follow-up or five years. Propensity models used 268 measured baseline covariates; false-discovery-rate correction addressed the many comparisons.
Twenty-one drug associations were statistically significant in the four-system analysis and appeared again in a TriNetX cohort of 339,180 eligible patients. Yet effect sizes often shrank in external data. Celecoxib, for example, had an odds ratio of 0.34 in FLAT-WHITE but 0.86 in TriNetX; ketorolac was 0.41 versus 0.94. That attenuation is a warning against reading the associations as prescriptions. People receive these drugs for different illnesses, and those illnesses, care patterns and follow-up can also alter recorded dementia risk.[1]
The distinction that matters
What the evidence pipeline actually did
The method separates the privacy result from the clinical claim that still needs testing.
Four health systems
Fit local models on 123,971 records
Patient-level data stayed at each site
Federated calculation
Exchange summary statistics once
Matched centralized estimates
External check
Repeat signals in 339,180 TriNetX records
21 associations remained observational
Privacy-preserving analysis does not remove causal uncertainty
Overlap weighting improved balance on measured factors, and negative controls plus E-values tested sensitivity to hidden bias. Even so, confidence-limit E-values ranged as low as 1.11, meaning modest unmeasured confounding could explain some signals. Informative censoring, miscoded diagnoses, treatment switching and misspecified propensity models remain possible. The method also assumes a common outcome model, handles binary rather than time-varying treatment and estimates an effect for the population where treatment groups overlap—not every patient.
For researchers, the result supports a governed route to multi-site screening of hypotheses. Data stewards would still need access controls, disclosure review and checks on whether summary outputs can leak information about small groups. For patients and clinicians, it does not support starting celecoxib, steroids, antibiotics or other flagged drugs to prevent dementia; several carry substantial harms, and earlier trials have not established such benefit. What would change the assessment is preregistered replication with transparent code, stronger designs addressing time-varying treatment and confounding, followed by randomized trials measuring cognition, dementia diagnoses and adverse events.[1]
Watch the background, then check the evidence
Illustrative photo · not a video frame
Google DeepMind · 1 min 52 sec · Background explainer
Protein folding explained
YouTube loads only when you choose; playback starts when you press play.
A short introduction to why a protein’s shape matters. It provides background for understanding what AI structure prediction contributes to biological research.
Evidence check: This is the developer’s explanation. Predicting a structure does not by itself establish a treatment’s safety or benefit for patients.
Published 2020-11-30. Source checked 14 October 2026. Check captions on the publisher’s video page.
Explore current researchContinue the story
Read next
Continue exploring federated learning: compare the finding and its evidence limits.
Keeping patient data local does not make an AI health claim causal
A peer-reviewed methods review maps how hospitals can estimate treatment effects without pooling patient records. Its central warning is practical: federation changes computation, not the assumptions needed for a causal conclusion or a real privacy guarantee.
Read the next reportExplore the full source and evidence record
What this means for people
- Hospitals may be able to collaborate without exporting patient-level records, but people with memory problems should not change medication on the basis of these retrospective signals.
Global context
The demonstration used US health systems and coding practices. Other countries would need locally harmonised definitions, governance review and validation before relying on the method or its drug signals.
What the evidence does not yet show
- Retrospective electronic-health-record study
- Residual confounding and informative censoring remain possible
- Drug exposure was simplified to binary initiation
- Common outcome-model assumption across sites
- Odds ratios do not directly express absolute risk
- No randomized treatment or patient-facing outcome trial
What to watch next
- Independent code and estimator replication
- Time-varying treatment extensions
- Preregistered emulations with stronger negative controls
- Randomized trials of plausible candidates
- Absolute benefits and adverse events
Living evidence record
Impact record IAI-1NJWBHX
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
27 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what npj Health Systems published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 27 October 2026
Research question, topics and regions
Whether multi-site target-trial emulations can reproduce pooled observational estimates without moving patient-level records, and what the resulting dementia-drug signals can support
Topics: Federated learning · Causal inference · Health data · Dementia · Drug repurposing
Regions: United States · North America · Global
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.